Interim Results of Vasomedical's MUST-EECP Trial Published in
Circulation
PR Newswire - October 29, 1997 10:15
WESTBURY, N.Y., Oct. 29 /PRNewswire/ -- Vasomedical, Inc. (Nasdaq: VASO)( vasomedical.com ) announced today that the interim results of MUST-EECP (Multicenter Study of Enhanced External Counterpulsation) have been published in abstract form* in Circulation, the official journal of the American Heart Association.
In the study, patients with Canadian Classification Society Classes I, II and III angina pectoris and a documented history of coronary artery disease, and in whom medicines were inadequate, were randomized in equal numbers to either active treatment or a sham treatment where the desired hemodynamic effects of EECP(R) were minimal or absent.
The interim results, which demonstrate both the safety and efficacy of EECP in treating myocardial ischemia in patients with severe coronary artery disease, are derived from an analysis of data from the first 84 patients in this 139-patient randomized, acebo-controlled, double-blinded trial.
As reported previously, full results of MUST-EECP will be presented at 2 p.m. on November 11, 1997 at the 70th Annual Scientific Sessions of the American Heart Association in Orlando, Florida. "The publication of this abstract heralds a long-awaited event, that is the presentation of MUST-EECP results in about two weeks' time," commented
Anthony Peacock, Vice President of Clinical Affairs for Vasomedical.
"Presentation of the full analysis will, no doubt, attract great attention from the cardiology community and the medical media both of whom have been following developments closely."
Angina pectoris, affecting more than seven million people in the United States, strikes when obstructed coronary arteries deprive the heart muscle of oxygen adequate to its needs. EECP is an outpatient procedure to relieve angina pectoris by improving perfusion of insufficiently supplied areas of the heart.
People suffering with angina pectoris may receive EECP therapy at
hospitals and clinics in many parts of the country. Equipment, treatment guidelines and staff training are provided by Vasomedical, Inc., Westbury, N.Y.
* Rohit R. Arora, M.D. et al. Results of the Multicenter study of Enhanced External Counterpulsation (MUST-EECP): EECP Reduces Anginal Episodes and Exercise-Induced Myocardial Ischemia. Supplement to Circulation, October 21, 1997; 96(8) 2602
SOURCE Vasomedical, Inc.
/CONTACT: Natalie Karp, Investor Relations of Vasomedical,516-997-4600, ext. 776/
(VASO) |
